{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:03:59Z","timestamp":1772118239561,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770126, 81800163 and 81570156"],"award-info":[{"award-number":["81770126, 81800163 and 81570156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016077","name":"Dongguan Science and Technology Bureau","doi-asserted-by":"publisher","award":["202050715001214"],"award-info":[{"award-number":["202050715001214"]}],"id":[{"id":"10.13039\/501100016077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02123-5","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T07:02:31Z","timestamp":1690441351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-\u03b3-dependent cytotoxic capacity"],"prefix":"10.1007","volume":"40","author":[{"given":"Yirong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoxin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangkun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-5462","authenticated-orcid":false,"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"5405","key":"2123_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0published","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD, Letter. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243(5405):290\u20133. https:\/\/doi.org\/10.1038\/243290a0published. Online First: 1973\/06\/01].","journal-title":"Nature"},{"issue":"Suppl 2","key":"2123_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M Hoglund","year":"2015","unstructured":"Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):241\u20137. : 10.1007\/s00277-015-2314-2published Online First: 2015\/03\/31].","journal-title":"Ann Hematol"},{"issue":"7","key":"2123_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4065\/81.7.973","volume":"81","author":"A Quintas-Cardama","year":"2006","unstructured":"Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81(7):973\u201388. : 10.4065\/81.7.973published Online First: 2006\/07\/14].","journal-title":"Mayo Clin Proc"},{"key":"2123_CR4","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A, Cancer statistics. 2023. CA Cancer J Clin 2023;73(1):17\u201348 doi: 10.3322\/caac.21763published Online First: 2023\/01\/13].","DOI":"10.3322\/caac.21763"},{"issue":"5","key":"2123_CR5","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186\u201393. https:\/\/doi.org\/10.1016\/S2352-3026(15. )00048-4published Online First: 2015\/12\/22].","journal-title":"Lancet Haematol"},{"issue":"1","key":"2123_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","volume":"10","author":"CY Ok","year":"2017","unstructured":"Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017;10(1):103. https:\/\/doi.org\/10.1186\/s13045-017-0474-3. published Online First: 2017\/05\/10].","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2123_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1600-0609.2008.01053.xpublished","volume":"80","author":"J Greiner","year":"2008","unstructured":"Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol. 2008;80(6):461\u20138. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01053.xpublished. Online First: 2008\/02\/21].","journal-title":"Eur J Haematol"},{"issue":"9460","key":"2123_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(05","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365(9460):657\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(05. )17945-8published Online First: 2005\/02\/22].","journal-title":"Lancet"},{"issue":"11","key":"2123_CR9","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","volume":"21","author":"JM Rojas","year":"2007","unstructured":"Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21(11):2287\u201395. https:\/\/doi.org\/10.1038\/sj.leu.2404858. published Online First: 2007\/07\/20].","journal-title":"Leukemia"},{"issue":"1","key":"2123_CR10","doi-asserted-by":"publisher","first-page":"e87794","DOI":"10.1371\/journal.pone.0087794","volume":"9","author":"M Ilander","year":"2014","unstructured":"Ilander M, Kreutzman A, Rohon P, et al. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS ONE. 2014;9(1):e87794. https:\/\/doi.org\/10.1371\/journal.pone.0087794. published Online First: 2014\/02\/06].","journal-title":"PLoS ONE"},{"issue":"5","key":"2123_CR11","first-page":"1671","volume":"6","author":"JM Reuben","year":"2000","unstructured":"Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res. 2000;6(5):1671\u20137. Online First: 2000\/05\/18].","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2123_CR12","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-04-0897","volume":"10","author":"H Kobayashi","year":"2004","unstructured":"Kobayashi H, Nagato T, Yanai M, et al. Recognition of adult T-cell leukemia\/lymphoma cells by CD4 + helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein. Clin Cancer Res. 2004;10(20):7053\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0897. published Online First: 2004\/10\/27].","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2123_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1084\/jem.20091921","volume":"207","author":"Y Xie","year":"2010","unstructured":"Xie Y, Akpinarli A, Maris C, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010;207(3):651\u201367. : 10.1084\/jem.20091921published Online First: 2010\/02\/17].","journal-title":"J Exp Med"},{"issue":"3","key":"2123_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637\u201350. : 10.1084\/jem.20091918published Online First: 2010\/02\/17].","journal-title":"J Exp Med"},{"issue":"1","key":"2123_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hep.26054","volume":"58","author":"J Fu","year":"2013","unstructured":"Fu J, Zhang Z, Zhou L, et al. Impairment of CD4 + cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology. 2013;58(1):139\u201349. : 10.1002\/hep.26054published Online First: 2012\/09\/11].","journal-title":"Hepatology"},{"issue":"6184","key":"2123_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4 + T cells in a patient with epithelial cancer. Science. 2014;344(6184):641\u20135. : 10.1126\/science.1251102published Online First: 2014\/05\/09].","journal-title":"Science"},{"issue":"12","key":"2123_CR17","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","volume":"109","author":"A Perez-Diez","year":"2007","unstructured":"Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007;109(12):5346\u201354. : 10.1182\/blood-2006-10-051318published Online First: 2007\/03\/01].","journal-title":"Blood"},{"key":"2123_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cellimm.2018.02.009","volume":"327","author":"X Zhang","year":"2018","unstructured":"Zhang X, Gao L, Meng K, et al. Characterization of CD4(+) T cell-mediated cytotoxicity in patients with multiple myeloma. Cell Immunol. 2018;327:62\u20137. https:\/\/doi.org\/10.1016\/j.cellimm.2018.02.009. published Online First: 2018\/02\/20].","journal-title":"Cell Immunol"},{"issue":"5168","key":"2123_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1126\/science.8016643","volume":"265","author":"V Steimle","year":"1994","unstructured":"Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994;265(5168):106\u20139. : 10.1126\/science.8016643published Online First: 1994\/07\/01].","journal-title":"Science"},{"issue":"11","key":"2123_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/s0145-2126(03)00072","volume":"27","author":"NE Day","year":"2003","unstructured":"Day NE, Ugai H, Yokoyama KK, Ichiki AT. K-562 cells lack MHC class II expression due to an alternatively spliced CIITA transcript with a truncated coding region. Leuk Res. 2003;27(11):1027\u201338. https:\/\/doi.org\/10.1016\/s0145-2126(03)00072. -9published Online First: 2003\/07\/16].","journal-title":"Leuk Res"},{"issue":"11","key":"2123_CR21","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.4049\/jimmunol.168.11.5954","volume":"168","author":"V Appay","year":"2002","unstructured":"Appay V, Zaunders JJ, Papagno L, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol. 2002;168(11):5954\u20138. https:\/\/doi.org\/10.4049\/jimmunol.168.11.5954. published Online First: 2002\/05\/23].","journal-title":"J Immunol"},{"issue":"3","key":"2123_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.coi.2008.03.007","volume":"20","author":"PJ van de Berg","year":"2008","unstructured":"van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R. Cytotoxic human CD4(+) T cells. Curr Opin Immunol. 2008;20(3):339\u201343. https:\/\/doi.org\/10.1016\/j.coi.2008.03.007. published Online First: 2008\/04\/29].","journal-title":"Curr Opin Immunol"},{"key":"2123_CR23","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.coi.2023","volume":"83","author":"E Bawden","year":"2023","unstructured":"Bawden E, Gebhardt T. The multifaceted roles of CD4(+) T cells and MHC class II in cancer surveillance. Curr Opin Immunol. 2023;83:102345. https:\/\/doi.org\/10.1016\/j.coi.2023. 102345published Online First: 2023\/05\/29].","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"2123_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/00002371-200105000-00002","volume":"24","author":"G Zeng","year":"2001","unstructured":"Zeng G. MHC class II-restricted tumor antigens recognized by CD4 + T cells: new strategies for cancer vaccine design. J Immunother. 2001;24(3):195\u2013204. Online First: 2001\/06\/08].","journal-title":"J Immunother"},{"issue":"7","key":"2123_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY, Kwek SS, Raju SS, et al. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder Cancer. Cell. 2020;181(7):1612\u201325e13. https:\/\/doi.org\/10.1016\/j.cell.2020.05.017. published Online First: 2020\/06\/05.","journal-title":"Cell"},{"issue":"6","key":"2123_CR26","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1182\/blood-2003-08","volume":"103","author":"JJ Zaunders","year":"2004","unstructured":"Zaunders JJ, Dyer WB, Wang B, et al. Identification of circulating antigen-specific CD4 + T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood. 2004;103(6):2238\u201347. https:\/\/doi.org\/10.1182\/blood-2003-08. -2765published Online First: 2003\/12\/03].","journal-title":"Blood"},{"issue":"5","key":"2123_CR27","doi-asserted-by":"publisher","first-page":"R292","DOI":"10.1186\/ar793","volume":"5","author":"C Duftner","year":"2003","unstructured":"Duftner C, Goldberger C, Falkenbach A, et al. Prevalence, clinical relevance and characterization of circulating cytotoxic CD4 + CD28- T cells in ankylosing spondylitis. Arthritis Res Ther. 2003;5(5):R292\u2013300. https:\/\/doi.org\/10.1186\/ar793. published Online First: 2003\/08\/23].","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2123_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cellimm.2010.02.008","volume":"262","author":"DM Brown","year":"2010","unstructured":"Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol. 2010;262(2):89\u201395. : 10.1016\/j.cellimm.2010.02.008published Online First: 2010\/03\/20].","journal-title":"Cell Immunol"},{"issue":"1","key":"2123_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1365-2249.2001.01639","volume":"126","author":"N Porakishvili","year":"2001","unstructured":"Porakishvili N, Roschupkina T, Kalber T, et al. Expansion of CD4 + T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol. 2001;126(1):29\u201336. https:\/\/doi.org\/10.1046\/j.1365-2249.2001.01639. .xpublished Online First: 2001\/10\/27].","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2123_CR30","first-page":"435","volume":"89","author":"N Porakishvili","year":"2004","unstructured":"Porakishvili N, Kardava L, Jewell AP, et al. Cytotoxic CD4 + T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica. 2004;89(4):435\u201343. Online First: 2004\/04\/13].","journal-title":"Haematologica"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02123-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T03:45:24Z","timestamp":1693453524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02123-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["2123"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02123-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All participants gave written informed consent. This study was performed in accordance with the Declaration of Helsinki and approved by Ethics Review Board of First Affiliated Hospital of Xiamen University, approval number (KY2017-004).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"253"}}